UY28203A1 - Formulaciones de glucocorticoides para el tratamiento de la angiogenesis ocular patologica. - Google Patents

Formulaciones de glucocorticoides para el tratamiento de la angiogenesis ocular patologica.

Info

Publication number
UY28203A1
UY28203A1 UY28203A UY28203A UY28203A1 UY 28203 A1 UY28203 A1 UY 28203A1 UY 28203 A UY28203 A UY 28203A UY 28203 A UY28203 A UY 28203A UY 28203 A1 UY28203 A1 UY 28203A1
Authority
UY
Uruguay
Prior art keywords
glucocorticoids
formulations
treatment
ocular angiogenesis
pathological ocular
Prior art date
Application number
UY28203A
Other languages
English (en)
Inventor
David P Bingaman
Abbot F Clark
Rajni Jani
Stella M Robertson
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of UY28203A1 publication Critical patent/UY28203A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Las formulaciones de glucocorticoides solos y en combinación con acetato de anecortave son útiles para prevenir y tratar la angiogénesis ocular patológica y los edemas asociadosl
UY28203A 2003-02-20 2004-02-19 Formulaciones de glucocorticoides para el tratamiento de la angiogenesis ocular patologica. UY28203A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44894403P 2003-02-20 2003-02-20

Publications (1)

Publication Number Publication Date
UY28203A1 true UY28203A1 (es) 2004-08-31

Family

ID=32908675

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28203A UY28203A1 (es) 2003-02-20 2004-02-19 Formulaciones de glucocorticoides para el tratamiento de la angiogenesis ocular patologica.

Country Status (16)

Country Link
US (2) US20060074061A1 (es)
EP (1) EP1594511A2 (es)
JP (2) JP2006518383A (es)
KR (1) KR20050102653A (es)
CN (1) CN100431544C (es)
AR (1) AR043252A1 (es)
AU (1) AU2004212900A1 (es)
BR (1) BRPI0407742A (es)
CA (1) CA2516790A1 (es)
MX (1) MXPA05008396A (es)
PL (1) PL378209A1 (es)
RU (1) RU2005129278A (es)
TW (1) TW200507858A (es)
UY (1) UY28203A1 (es)
WO (1) WO2004073608A2 (es)
ZA (1) ZA200505990B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1852700A (zh) * 2003-09-23 2006-10-25 爱尔康公司 曲安奈德和醋酸阿奈可他注射用制剂
US7257366B2 (en) * 2003-11-26 2007-08-14 Osmosis Llc System and method for teaching a new language
JP2009507845A (ja) * 2005-09-07 2009-02-26 サウスウエスト リサーチ インスティテュート 改良された放出速度を示す生分解性微粒子薬学的処方物
US9693967B2 (en) 2005-09-07 2017-07-04 Southwest Research Institute Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates
TW200731984A (en) * 2005-12-22 2007-09-01 Alcon Mfg Ltd C3-convertase inhibitors for the prevention and treatment of age-related macular degeneration in patients with at risk variants of complement factor H
US20070173538A1 (en) * 2005-12-23 2007-07-26 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
GB0625844D0 (en) * 2006-12-22 2007-02-07 Daniolabs Ltd The treatment of macular degeneration
JP2010534201A (ja) * 2007-07-20 2010-11-04 アルコン，インコーポレイテッド 受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の目への送達のための医薬製剤
WO2011141456A1 (en) * 2010-05-10 2011-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
US20170106047A1 (en) * 2014-06-12 2017-04-20 The Research Foundation For The State University Of New York Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975537A (en) * 1985-10-23 1990-12-04 The Upjohn Company Δ9(11) -angiostatic steroids
US4686214A (en) * 1985-10-30 1987-08-11 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
US4771042A (en) * 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US5371078A (en) * 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
AU684115B2 (en) * 1993-12-27 1997-12-04 Mitsubishi Chemical Corporation Ophthalmic suspension containing diflupredonate
US5646136A (en) * 1994-01-04 1997-07-08 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids
US5516522A (en) * 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
US6413245B1 (en) * 1999-10-21 2002-07-02 Alcon Universal Ltd. Sub-tenon drug delivery
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
AU768400B2 (en) * 1999-10-21 2003-12-11 Alcon Inc. Drug delivery device
PL375024A1 (en) * 2002-08-05 2005-11-14 Alcon, Inc. Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration

Also Published As

Publication number Publication date
EP1594511A2 (en) 2005-11-16
MXPA05008396A (es) 2006-03-30
RU2005129278A (ru) 2006-01-27
CN100431544C (zh) 2008-11-12
AU2004212900A1 (en) 2004-09-02
US20040167109A1 (en) 2004-08-26
WO2004073608A2 (en) 2004-09-02
JP2007056041A (ja) 2007-03-08
KR20050102653A (ko) 2005-10-26
TW200507858A (en) 2005-03-01
CN1750829A (zh) 2006-03-22
JP2006518383A (ja) 2006-08-10
WO2004073608A3 (en) 2005-03-24
ZA200505990B (en) 2006-12-27
AR043252A1 (es) 2005-07-20
BRPI0407742A (pt) 2006-02-14
CA2516790A1 (en) 2004-09-02
PL378209A1 (pl) 2006-03-20
US20060074061A1 (en) 2006-04-06

Similar Documents

Publication Publication Date Title
MXPA05012784A (es) Lipidos oxidados y usos de los mismos en el tratamiento de enfermedades y desordenes inflamatorios.
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
EA200601648A1 (ru) Глюкозамин и общие пролекарства глюкозамин/противовоспалительный агент, композиции и способы
AR028296A1 (es) Metodos sinergisticos y composiciones para el tratamiento del cancer
HN2005029978A (es) Formulaciones
UY26058A1 (es) Compuestos utiles como antiinflamatorios ley 17.164 art. 127
MX2007016462A (es) Composiciones topicas para tratar la piel.
UY26186A1 (es) Inhibidores de metaloproteasas
DE50312034D1 (de) Liposomale glucocorticoide
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
UY28203A1 (es) Formulaciones de glucocorticoides para el tratamiento de la angiogenesis ocular patologica.
PE20050477A1 (es) Terapia de combinacion para la infeccion de hcv
ECSP055823A (es) DERIVADOS DE [6,7-DIHIDRO-5H-IMIDAZO[1,2-a]IMIDAZOL-3-SULFONILAMINO]-PROPIONAMIDA
AR045943A1 (es) Formulaciones de acetonido de triamcinolona y acetato de anecortave para inyeccion
CL2008000495A1 (es) Compuestos derivados de tetrahidro-pirazolo[4,3-c]piridina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como alergias, inflamacion, dolor, cancer, entreotras.
ATE391493T1 (de) Suspension von loteprednol-etabonat und tobramycin für die topische ophthalmische anwendung
HN2003000080A (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso
MY135829A (en) Analeptic and drug combinations
ES2150705T3 (es) Derivados de ester de nitrito esteroideos utiles como farmacos antiinflamatorios.
AR057648A1 (es) Composicion de metaflumizona para la administracion topica
MXPA05008561A (es) Uso de esteroides para tratar personas que sufren de trastornos oculares.
GT200400241A (es) Prevencion y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de los estrogenos selectivos8b-vinil-estra-1,3,5,(10)-trien-3,17b-diol y 17b-fluor-9a-vinil-estra-1,3,6,(10)-trien-3, 16a-diol
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
DE602004009414D1 (de) BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN MIT N-2,3,3-TETRAMETHYLBICYCLOi2.2.1öHEPTAN-2-AMINE
ATE427122T1 (de) Behandlung von dermatitis mit dehydroepiandrosteron-glucocorticoid- kombinationen

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20140818